PHIL unveiled its direct-to-patient 2.0 platform designed to improve pharmaceutical access and adherence by integrating coverage-first workflows, telemedicine, prescription fulfillment, real-time support, and affordability solutions. Addressing growing consumer demand and cost barriers, particularly in high-cost categories like GLP-1 therapies for obesity, the platform aims to bridge insurance coverage gaps and reduce treatment discontinuation caused by high out-of-pocket expenses. PHIL’s model leverages digital tools to accelerate therapy initiation and retention, promising better health outcomes and streamlined patient support.